The Food and Drug Administration's Osteoporosis Guidance Document: Past, Present, and Future

Journal of Bone and Mineral Research

Volumn 18, Issue 6, 2003, Pages 1125-1128

  Colman, Eric G ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM FLUORIDE; ESTROGEN; ETIDRONIC ACID; FLUORIDE SODIUM; GESTAGEN; RALOXIFENE; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BONE MASS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG USE; FEMALE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HORMONE SUBSTITUTION; HUMAN; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

BIOMEDICAL AND BEHAVIORAL RESEARCH;

FEMALE; HUMAN EXPERIMENTATION; HUMANS; OSTEOPOROSIS; POSTMENOPAUSE; QUALITY ASSURANCE, HEALTH CARE; RESEARCH DESIGN; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0142091171     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2003.18.6.1125     Document Type: Conference Paper

References (15)

1. Office of Freedom of Information 1971) Guidelines for the Clinical Evaluation of Drugs Used in the Treatment of Osteoporosis. Department of Health and Human Services, Rockville, MD, USA.
2. Colman E, Hedin R, Swann J, Orloff D 2002 A brief history of calcitonin. Lancet 359:885-886.
3. Office of Freedom of Information 1984 Guidelines for the Clinical Evaluation of Drugs Used in the Treatment or Prevention of Osteoporosis. Department of Health and Human Services, Rockville, MD, USA.
4. Riggs BL, Seeman E, Hodgson SF, Taves DR, O'Fallon WM 1982 Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis. Comparison with conventional therapy. N Engl J Med 306:446-450.
5. Riggs BL, Hodgson SF, O'Fallon WM, Chao EY, Wahner HW, Muhs JM, Cedel SL, Melton LJ 1990 Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 322:802-809.
6. Anonymous 1990 Fluoride not helpful, and possibly harmful, in osteoporosis. J Watch Gen Med 2:1-2.
7. Office of Freedom of Information 1981 Proceedings of the Endocrinologic and Metabolic Drugs Advisory Committee Meeting. Rockville, MD, USA.
8. Office of Freedom of Information 1994 Guidelines for Preclinical and Clinical Evaluation of Agents Used in the Prevention or Treatment of Postmenopausal Osteoporosis. Department of Health and Human Services, Rockville, MD, USA.
9. Office of Freedom of Information 1995 Medical Officer Review of Alendronate New Drug Application. Department of Health and Human Services, Rockville, MD, USA.
10. Office of Freedom of Information 1998 Medical Officer Review of Risedronate New Drug Application. Department of Health and Human Services. Rockville, MD, USA.
11. 1974 Physicians' Desk Reference. Medical Economics Company, Montvale, NJ, USA.
12. Office of Freedom of Information 1997 Medical Officer Review of Raloxifene New Drug Application. Department of Health and Human Services, Rockville, MD, USA.
13. Writing Group for the Women's Health Initiative Investigators 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288:321-333.
14. World Medical Association. Declaration of Helsinki (as revised). Available online at www.wma.net/e/policy/17-c_e.html. Accessed on June 25, 2002.
15. Kanis JA, Oden A, Johnell O, Caulin F, Bone H, Alexandre J-M, Abadie E, Lekkerkerker F 2002 Uncertain future of trials in osteoporosis. Osteoporos Int 13:443-449.